Drugs / COVAX
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT05065892 | Oct 2021 → Jan 2022 | pneumonia | China National Biotec Group Company Limited | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-07-12 | China National Biotec Group Company Limited | Regulatory 国药集团中国生物与GAVI签署COVAX供应协议 cnbg.com.cn ↗
北京，2021年7月7日，国药集团中国生物北京生物制品研究所与全球疫苗免疫联盟（Gavi）签署了首个新冠灭活疫苗预购协议(APA)。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-07-12 | China National Biotec Group Company Limited | 国药集团中国生物与GAVI签署COVAX供应协议 cnbg.com.cn ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COVAX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05065892 ↗ |
| Modality | Vaccine | “inactivated SARS-CoV-2 vaccine (Vero cells)” NCT05065892 ↗ |